



Supplementary Material



Supplementary Figure 1 The correlation heatmap of the predictor variables.



Supplementary Figure 2 A screenshot of the application interface.

Supplementary Table 1 Baseline characteristics of GC patients before and after Propensity Score Matching: neoadjuvant chemotherapy group versus combination therapy group (with targeted or immunotherapy)

	Before PSM			After PSM		
	Chemotherapy group	Combination therapy group	<i>P</i> value	Chemotherapy group	Combination therapy group	<i>P</i> value
<i>N</i>	344	60		53	53	
Age, yr, mean (SD)	58.98 (12.04)	51.67 (23.34)	<0.001	53.96 (17.24)	51.60 (23.50)	0.557
Sex = male (%)	253 (73.5)	47 (78.3)	0.534	43 (81.1)	40 (75.5)	0.637
BMI, mean (SD)	23.68 (3.16)	22.93 (3.29)	0.093	23.19 (3.12)	23.08 (3.17)	0.851
Smoke = yes (%)	161 (46.8)	36 (60.0)	0.081	35 (66.0)	33 (62.3)	0.839
Alcohol = yes (%)	105 (30.5)	24 (40.0)	0.193	18 (34.0)	21 (39.6)	0.687
Combination of other diseases = yes (%)	154 (44.8)	30 (50.0)	0.542	26 (49.1)	27 (50.9)	1
Hypertension = yes (%)	103 (29.9)	21 (35.0)	0.527	13 (24.5)	19 (35.8)	0.29
Diabetes = yes (%)	59 (17.2)	14 (23.3)	0.334	12 (22.6)	11 (20.8)	1
Reflux oesophagitis = yes (%)	13 (3.8)	0 (0.0)	0.257	2 (3.8)	0 (0.0)	0.475
Pyloric obstruction = yes (%)	26 (7.6)	2 (3.3)	0.361	4 (7.5)	2 (3.8)	0.674
Anxiety depression = yes (%)	4 (1.2)	0 (0.0)	0.894	53 (100.0)	53 (100.0)	NA

Abdomino-pelvic surgery history history = yes (%)	81 (23.5)	18 (30.0)	0.363	10 (18.9)	17 (32.1)	0.181
Thyroid dysfunction = yes (%)	2 (0.6)	2 (3.3)	0.2	1 (1.9)	2 (3.8)	1
HP infection = yes (%)	39 (11.3)	1 (1.7)	0.038	2 (3.8)	1 (1.9)	1
Family history of tumor = yes (%)	68 (19.8)	17 (28.3)	0.183	15 (28.3)	15 (28.3)	1
location (%)			0.008			0.843
diffuse	35 (10.2)	7 (11.7)		8 (15.1)	6 (11.3)	
distal	268 (77.9)	37 (61.7)		33 (62.3)	34 (64.2)	
preximal	41 (11.9)	16 (26.7)		12 (22.6)	13 (24.5)	
Clinical stage (%)			<0.001			0.719
L1	44 (12.8)	1 (1.7)		0 (0.0)	1 (1.9)	
L2	137 (39.8)	17 (28.3)		15 (28.3)	17 (32.1)	
L3	147 (42.7)	28 (46.7)		27 (50.9)	26 (49.1)	
L4	16 (4.7)	14 (23.3)		11 (20.8)	9 (17.0)	
ASA status (%)			0.073			0.116
L1	46 (13.4)	2 (3.3)		8 (15.1)	2 (3.8)	
L2	232 (67.4)	47 (78.3)		34 (64.2)	41 (77.4)	
L3	66 (19.2)	11 (18.3)		11 (20.8)	10 (18.9)	

Cardiac function (%)			0.15			
L1	234 (68.0)	48 (80.0)				
L2	106 (30.8)	12 (20.0)		11 (20.8)	12 (22.6)	1
L3	4 (1.2)	0 (0.0)				
NRS2002 ≥ 3 = yes (%)	110 (32.0)	31 (51.7)	0.005	22 (41.5)	24 (45.3)	0.845
WBC (%)			0.755			1
High	7 (2.0)	2 (3.3)		2 (3.8)	2 (3.8)	
Low	35 (10.2)	5 (8.3)		5 (9.4)	5 (9.4)	
Normal	302 (87.8)	53 (88.3)		46 (86.8)	46 (86.8)	
Hgb (%)			0.085			0.358
High	18 (5.2)	1 (1.7)		4 (7.5)	1 (1.9)	
Low	60 (17.4)	17 (28.3)		14 (26.4)	13 (24.5)	
Normal	266 (77.3)	42 (70.0)		35 (66.0)	39 (73.6)	
ALB = normal (%)	332 (96.5)	56 (93.3)	0.42	51 (96.2)	52 (98.1)	1
A/G = normal (%)	343 (99.7)	60 (100.0)	1	53 (100.0)	53 (100.0)	NA
G = normal (%)	274 (79.7)	48 (80.0)	1	39 (73.6)	43 (81.1)	0.486
Surgical approach (%)			0.038			0.842

Distal-Billroth 1	141 (41.0)	13 (21.7)		15 (28.3)	13 (24.5)	
Distal-Billroth 2	4 (1.2)	2 (3.3)		2 (3.8)	2 (3.8)	
Distal-Roux-en-y	58 (16.9)	10 (16.7)		7 (13.2)	9 (17.0)	
Proximal	4 (1.2)	1 (1.7)		1 (1.9)	0 (0.0)	
Total-Roux-en-Y	137 (39.8)	34 (56.7)		28 (52.8)	29 (54.7)	
Intraoperative blood transfusion = yes (%)	19 (5.5)	2 (3.3)	0.697	3 (5.7)	0 (0.0)	0.241
Implantatio of enteral nutrition tubes = yes (%)	163 (47.4)	34 (56.7)	0.235	21 (39.6)	29 (54.7)	0.173
Intraoperative gastroscopy = yes (%)	18 (5.2)	0 (0.0)	0.141	2 (3.8)	0 (0.0)	0.475
Operating time > 4 h = yes (%)	155 (45.1)	22 (36.7)	0.286	17 (32.1)	20 (37.7)	0.684
Blood loss > 100 mL = yes (%)	101 (29.4)	20 (33.3)	0.64	19 (35.8)	16 (30.2)	0.68

Supplementary Table 2 Baseline characteristics of GC patients before and after PSM: neoadjuvant chemoradiotherapy group versus combination therapy group (with targeted or immunotherapy)

	Before PSM			After PSM		
	Chemoradiotherapy group	Combination therapy group	<i>P</i> value	Chemoradiotherapy group	Combination therapy group	<i>P</i> value
<i>N</i>	51	60		24	24	
Age, yr, mean (SD)	61.02 (9.98)	51.67 (23.34)	0.009	58.04 (10.05)	56.92 (18.91)	0.798
Sex = male (%)	42 (82.4)	47 (78.3)	0.771	19 (79.2)	17 (70.8)	0.739
BMI, mean (SD)	23.59 (3.49)	22.93 (3.29)	0.306	22.88 (3.33)	23.67 (3.09)	0.401
Smoke = yes (%)	28 (54.9)	36 (60.0)	0.727	13 (54.2)	16 (66.7)	0.555
Alcohol = yes (%)	20 (39.2)	24 (40.0)	1	10 (41.7)	10 (41.7)	1
Combination of other diseases = yes (%)	25 (49.0)	30 (50.0)	1	11 (45.8)	10 (41.7)	1
Hypertension = yes (%)	17 (33.3)	21 (35.0)	1	8 (33.3)	9 (37.5)	1
Diabetes = yes (%)	10 (19.6)	14 (23.3)	0.807	4 (16.7)	5 (20.8)	1
Reflux oesophagitis = yes (%)	2 (3.9)	0 (0.0)	0.405	1 (4.2)	0 (0.0)	1
Pyloric obstruction = yes (%)	0 (0.0)	2 (3.3)	0.549	24 (100.0)	24 (100.0)	NA
Anxiety depression = yes (%)	51 (100.0)	60 (100.0)	NA	24 (100.0)	24 (100.0)	NA

Abdomino-pelvic surgery history = yes (%)	17 (33.3)	18 (30.0)	0.864	6 (25.0)	5 (20.8)	1
Thyroid dysfunction = yes (%)	2 (3.9)	2 (3.3)	1	2 (8.3)	1 (4.2)	1
HP infection = yes (%)	4 (7.8)	1 (1.7)	0.269	2 (8.3)	0 (0.0)	0.47
Family history of tumor = yes (%)	12 (23.5)	17 (28.3)	0.721	5 (20.8)	3 (12.5)	0.699
Location (%)			<0.001			0.693
Diffuse	10 (19.6)	7 (11.7)		6 (25.0)	4 (16.7)	
Distal	6 (11.8)	37 (61.7)		5 (20.8)	7 (29.2)	
Preximal	35 (68.6)	16 (26.7)		13 (54.2)	13 (54.2)	
Clinical stage (%)			0.001			
L1	2 (3.9)	1 (1.7)				
L2	25 (49.0)	17 (28.3)				
L3	24 (47.1)	28 (46.7)				
L4	0 (0.0)	14 (23.3)		15 (62.5)	11 (45.8)	0.385
ASA status (%)			0.213			0.36
L1	6 (11.8)	2 (3.3)		4 (16.7)	1 (4.2)	
L2	35 (68.6)	47 (78.3)		17 (70.8)	20 (83.3)	
L3	10 (19.6)	11 (18.3)		3 (12.5)	3 (12.5)	

Cardiac function (%)			0.029			
L1	30 (58.8)	48 (80.0)				
L2	19 (37.3)	12 (20.0)		8 (33.3)	5 (20.8)	0.516
L3	2 (3.9)	0 (0.0)				
NRS2002 ≥ 3 = yes (%)	20 (39.2)	31 (51.7)	0.262	9 (37.5)	11 (45.8)	0.77
WBC (%)			0.049			0.578
High	1 (2.0)	2 (3.3)		1 (4.2)	1 (4.2)	
Low	13 (25.5)	5 (8.3)		1 (4.2)	3 (12.5)	
Normal	37 (72.5)	53 (88.3)		22 (91.7)	20 (83.3)	
Hgb (%)			0.2			0.506
High	4 (7.8)	1 (1.7)		1 (4.2)	0 (0.0)	
Low	10 (19.6)	17 (28.3)		5 (20.8)	7 (29.2)	
Normal	37 (72.5)	42 (70.0)		18 (75.0)	17 (70.8)	
ALB = normal (%)	47 (92.2)	56 (93.3)	1	22 (91.7)	24 (100.0)	0.47
A/G = normal (%)	50 (98.0)	60 (100.0)	0.935	23 (95.8)	24 (100.0)	1
G = normal (%)	38 (74.5)	48 (80.0)	0.644	19 (79.2)	19 (79.2)	1
Surgical approach (%)			<0.001			0.491

Distal-Billroth 1	1 (2.0)	13 (21.7)		1 (4.2)	2 (8.3)	
Distal-Billroth 2	0 (0.0)	2 (3.3)				
Distal-Roux-en-y	0 (0.0)	10 (16.7)				
Proximal	3 (5.9)	1 (1.7)		0 (0.0)	1 (4.2)	
Total-Roux-en-Y	47 (92.2)	34 (56.7)		23 (95.8)	21 (87.5)	
Intraoperative blood transfusion = yes (%)	1 (2.0)	2 (3.3)	1	24 (100.0)	24 (100.0)	NA
Implantatio of enteral nutrition tubes = yes (%)	21 (41.2)	34 (56.7)	0.151	11 (45.8)	16 (66.7)	0.244
Intraoperative gastroscopy = yes (%)	51 (100.0)	60 (100.0)	NA	24 (100.0)	24 (100.0)	NA
Operating time > 4 h = yes (%)	24 (47.1)	22 (36.7)	0.361	11 (45.8)	11 (45.8)	1
Blood loss > 100 mL = yes (%)	13 (25.5)	20 (33.3)	0.489	6 (25.0)	8 (33.3)	0.751

Supplementary Table 3 Baseline characteristics of GC patients before and after PSM: neoadjuvant chemotherapy group versus chemoradiotherapy

	Chemotherapy group	Chemoradiotherapy group	<i>P</i> value	Chemotherapy group	Chemoradiotherapy group	<i>P</i> value
<i>N</i>	344	51		40	40	
Age, yr, mean (SD)	58.98 (12.04)	61.02 (9.98)	0.25	60.15 (8.75)	62.33 (9.31)	0.285
Sex = male (%)	253 (73.5)	42 (82.4)	0.239	34 (85.0)	34 (85.0)	1
BMI, mean (SD)	23.68 (3.16)	23.59 (3.49)	0.855	23.74 (2.88)	23.87 (3.55)	0.856
Smoke = yes (%)	161 (46.8)	28 (54.9)	0.352	21 (52.5)	23 (57.5)	0.822
Alcohol = yes (%)	105 (30.5)	20 (39.2)	0.278	10 (25.0)	18 (45.0)	0.101
Combination of other diseases = yes (%)	154 (44.8)	25 (49.0)	0.676	15 (37.5)	20 (50.0)	0.367
Hypertension = yes (%)	103 (29.9)	17 (33.3)	0.743	8 (20.0)	15 (37.5)	0.138
Diabetes = yes (%)	59 (17.2)	10 (19.6)	0.815	8 (20.0)	7 (17.5)	1
Reflux oesophagitis = yes (%)	13 (3.8)	2 (3.9)	1	1 (2.5)	1 (2.5)	1
Pyloric obstruction = yes (%)	26 (7.6)	0 (0.0)	0.084	1 (2.5)	0 (0.0)	1
Anxiety depression = yes (%)	4 (1.2)	0 (0.0)	0.98	40 (100.0)	40 (100.0)	NA
Abdomino-pelvic surgery history = yes (%)	81 (23.5)	17 (33.3)	0.181	4 (10.0)	13 (32.5)	0.029

Thyroid dysfunction = yes (%)	2 (0.6)	2 (3.9)	0.14	0 (0.0)	2 (5.0)	0.474
HP infection = yes (%)	39 (11.3)	4 (7.8)	0.612	3 (7.5)	2 (5.0)	1
Family history of tumor = yes (%)	68 (19.8)	12 (23.5)	0.662	11 (27.5)	7 (17.5)	0.422
Location (%)			<0.001			0.826
Diffuse	35 (10.2)	10 (19.6)		6 (15.0)	7 (17.5)	
Distal	268 (77.9)	6 (11.8)		8 (20.0)	6 (15.0)	
Preximal	41 (11.9)	35 (68.6)		26 (65.0)	27 (67.5)	
Clinical stage (%)			0.09			0.718
L1	44 (12.8)	2 (3.9)		1 (2.5)	2 (5.0)	
L2	137 (39.8)	25 (49.0)		22 (55.0)	19 (47.5)	
L3	147 (42.7)	24 (47.1)		17 (42.5)	19 (47.5)	
L4	16 (4.7)	0 (0.0)				
ASA status (%)			0.951			0.734
L1	46 (13.4)	6 (11.8)		4 (10.0)	5 (12.5)	
L2	232 (67.4)	35 (68.6)		24 (60.0)	26 (65.0)	
L3	66 (19.2)	10 (19.6)		12 (30.0)	9 (22.5)	
Cardiac function (%)			0.185			0.58

L1	234 (68.0)	30 (58.8)		26 (65.0)	23 (57.5)	
L2	106 (30.8)	19 (37.3)		12 (30.0)	16 (40.0)	
L3	4 (1.2)	2 (3.9)		2 (5.0)	1 (2.5)	
NRS2002 ≥ 3 = yes (%)	110 (32.0)	20 (39.2)	0.386	10 (25.0)	17 (42.5)	0.156
WBC (%)			0.008			0.821
High	7 (2.0)	1 (2.0)		1 (2.5)	1 (2.5)	
Low	35 (10.2)	13 (25.5)		7 (17.5)	5 (12.5)	
Normal	302 (87.8)	37 (72.5)		32 (80.0)	34 (85.0)	
Hgb (%)			0.673			0.819
High	18 (5.2)	4 (7.8)		1 (2.5)	2 (5.0)	
Low	60 (17.4)	10 (19.6)		8 (20.0)	7 (17.5)	
Normal	266 (77.3)	37 (72.5)		31 (77.5)	31 (77.5)	
ALB = normal (%)	332 (96.5)	47 (92.2)	0.275	38 (95.0)	37 (92.5)	1
A/G = normal (%)	343 (99.7)	50 (98.0)	0.609	40 (100.0)	39 (97.5)	1
G = normal (%)	274 (79.7)	38 (74.5)	0.511	33 (82.5)	30 (75.0)	0.585
Surgical approach (%)			<0.001			1
Distal-Billroth 1	141 (41.0)	1 (2.0)		1 (2.5)	1 (2.5)	

Distal-Billroth 2	4 (1.2)	0 (0.0)				
Distal-Roux-en-y	58 (16.9)	0 (0.0)				
Proximal	4 (1.2)	3 (5.9)		2 (5.0)	2 (5.0)	
Total-Roux-en-Y	137 (39.8)	47 (92.2)		37 (92.5)	37 (92.5)	
Intraoperative blood transfusion = yes (%)	19 (5.5)	1 (2.0)	0.459	2 (5.0)	0 (0.0)	0.474
Implantatio of enteral nutrition tubes = yes (%)	163 (47.4)	21 (41.2)	0.497	19 (47.5)	17 (42.5)	0.822
Intraoperative gastroscopy = yes (%)	18 (5.2)	0 (0.0)	0.189	1 (2.5)	0 (0.0)	1
Operating time > 4 h = yes (%)	155 (45.1)	24 (47.1)	0.907	19 (47.5)	19 (47.5)	1
Blood loss > 100 mL = yes (%)	101 (29.4)	13 (25.5)	0.686	14 (35.0)	11 (27.5)	0.63

Supplementary Table 4 Results of Chi-Square analysis for complications among patients with different neoadjuvant therapy regimens after PSM

Treatment group comparison	Group 1 (<i>n</i>)	Group 2 (<i>n</i>)	Complications in group 1, <i>n</i> (%)	Complications in group 2, <i>n</i> (%)	<i>P</i> value
Chemotherapy <i>vs</i> chemoradiotherapy	Chemo (40)	Chemoradio (40)	9 (22.5)	7 (17.5)	0.78
Chemoradiotherapy <i>vs</i> combination therapy	Chemoradio (24)	Combi (24)	3 (12.5)	5 (20.8)	0.7
Chemotherapy <i>vs</i> combination therapy	Chemo (53)	Combi (53)	9 (17.0)	14 (26.4)	0.35

Chemo: Chemotherapy; Chemoradio: Chemoradiotherapy; Combi: Combination therapy.

Supplementary Table 5 Baseline characteristics and results of univariate analysis

	All	No	Yes	Univariate analysis		N
	N = 455	N = 386	N = 69	OR	P value	
Age, yr	61.0 (52.0-68.0)	61.0 (52.2-67.0)	62.0 (51.0-68.0)	1.00 (0.98-1.02)	0.809	455
Sex:					0.045	455
Female	113 (24.8%)	103 (26.7%)	10 (14.5%)	Ref.		
Male	342 (75.2%)	283 (73.3%)	59 (85.5%)	2.12 (1.09-4.57)		
Preoperative stay	6.00 (4.00-8.00)	6.00 (4.00-8.00)	7.00 (5.00-10.0)	1.06 (1.01-1.12)	0.104	455
Smoking					<0.001	455
No	230 (50.5%)	209 (54.1%)	21 (30.4%)	Ref.		
Yes	225 (49.5%)	177 (45.9%)	48 (69.6%)	2.68 (1.56-4.75)		
Alcohol:					0.596	455
No	306 (67.3%)	262 (67.9%)	44 (63.8%)	Ref.		
Yes	149 (32.7%)	124 (32.1%)	25 (36.2%)	1.20 (0.69-2.04)		
Hypertension:					0.973	455
No	314 (69.0%)	267 (69.2%)	47 (68.1%)	Ref.		

Yes	141 (31.0%)	119 (30.8%)	22 (31.9%)	1.05 (0.60-1.81)		
Diabetes:					0.713	455
No	372 (81.8%)	314 (81.3%)	58 (84.1%)	Ref.		
Yes	83 (18.2%)	72 (18.7%)	11 (15.9%)	0.84 (0.40-1.62)		
Reflux oesophagitis:					1	455
No	440 (96.7%)	373 (96.6%)	67 (97.1%)	Ref.		
Yes	15 (3.30%)	13 (3.37%)	2 (2.90%)	0.91 (0.13-3.44)		
Pyloric obstruction:					0.596	455
No	427 (93.8%)	363 (94.0%)	64 (92.8%)	Ref.		
Yes	28 (6.15%)	23 (5.96%)	5 (7.25%)	1.26 (0.40-3.22)		
Anxiety or depression:					0.483	455
No	451 (99.1%)	383 (99.2%)	68 (98.6%)	Ref.		
Yes	4 (0.88%)	3 (0.78%)	1 (1.45%)	2.04 (0.07-17.8)		
Other diseases:					0.959	455
No	246 (54.1%)	208 (53.9%)	38 (55.1%)	Ref.		
Yes	209 (45.9%)	178 (46.1%)	31 (44.9%)	0.95 (0.57-1.60)		

Abdomino-pelvic surgery history:					0.354	455
No	339 (74.5%)	284 (73.6%)	55 (79.7%)	Ref.		
Yes	116 (25.5%)	102 (26.4%)	14 (20.3%)	0.71 (0.37-1.31)		
Thyroid dysfunction:					1	455
No	449 (98.7%)	381 (98.7%)	68 (98.6%)	Ref.		
Yes	6 (1.32%)	5 (1.30%)	1 (1.45%)	1.24 (0.05-8.25)		
HP infection:					0.714	455
No	411 (90.3%)	350 (90.7%)	61 (88.4%)	Ref.		
Yes	44 (9.67%)	36 (9.33%)	8 (11.6%)	1.29 (0.53-2.80)		
Family history of tumors:					0.801	455
No	358 (78.7%)	305 (79.0%)	53 (76.8%)	Ref.		
Yes	97 (21.3%)	81 (21.0%)	16 (23.2%)	1.14 (0.60-2.07)		
Location:					0.067	455
Diffuse	52 (11.4%)	46 (11.9%)	6 (8.70%)	Ref.		
Distal	311 (68.4%)	269 (69.7%)	42 (60.9%)	1.17 (0.50-3.26)		

Preximal	92 (20.2%)	71 (18.4%)	21 (30.4%)	2.22 (0.87-6.53)		
Clinical stage:					0.935	455
L1	47 (10.3%)	40 (10.4%)	7 (10.1%)	Ref.		
L2	179 (39.3%)	154 (39.9%)	25 (36.2%)	0.92 (0.38-2.46)		
L3	199 (43.7%)	167 (43.3%)	32 (46.4%)	1.08 (0.46-2.85)		
L4	30 (6.59%)	25 (6.48%)	5 (7.25%)	1.15 (0.30-4.10)		
ASA status					<0.001	455
L1	54 (11.9%)	48 (12.4%)	6 (8.70%)	Ref.		
L2	314 (69.0%)	279 (72.3%)	35 (50.7%)	0.98 (0.42-2.75)		
L3	87 (19.1%)	59 (15.3%)	28 (40.6%)	3.70 (1.49-10.7)		
Cardiac function:					0.403	455
L1	312 (68.6%)	269 (69.7%)	43 (62.3%)	Ref.		
L2	137 (30.1%)	112 (29.0%)	25 (36.2%)	1.40 (0.80-2.39)		
L3	6 (1.32%)	5 (1.30%)	1 (1.45%)	1.38 (0.05-9.30)		
BMI	23.5 (21.3-25.8)	23.5 (21.2-25.8)	23.1 (21.9-26.1)	1.02 (0.94-1.11)	0.525	455
Neoadjuvant strategy:					0.008	455

Chemotherapy	344 (75.6%)	300 (77.7%)	44 (63.8%)	Ref.		
Immuno/targeted	60 (13.2%)	43 (11.1%)	17 (24.6%)	2.70 (1.38-5.10)		
Chemoradiotherapy	51 (11.2%)	43 (11.1%)	8 (11.6%)	1.28 (0.53-2.80)		
NRS2002 ≥3:					<0.001	455
No	294 (64.6%)	265 (68.7%)	29 (42.0%)	Ref.		
Yes	161 (35.4%)	121 (31.3%)	40 (58.0%)	3.01 (1.78-5.13)		
WBC:					0.077	455
High	10 (2.20%)	6 (1.55%)	4 (5.80%)	Ref.		
Low	53 (11.6%)	47 (12.2%)	6 (8.70%)	0.20 (0.04-1.00)		
Normal	392 (86.2%)	333 (86.3%)	59 (85.5%)	0.26 (0.07-1.10)		
HGB:					0.465	455
High	23 (5.05%)	18 (4.66%)	5 (7.25%)	Ref.		
Low	87 (19.1%)	72 (18.7%)	15 (21.7%)	0.74 (0.25-2.58)		
Normal	345 (75.8%)	296 (76.7%)	49 (71.0%)	0.58 (0.22-1.87)		
Alb:					1	455
Low	20 (4.40%)	17 (4.40%)	3 (4.35%)	Ref.		

Normal	435 (95.6%)	369 (95.6%)	66 (95.7%)	0.97 (0.31-4.44)		
A/G:					0.281	455
Low	2 (0.44%)	1 (0.26%)	1 (1.45%)	Ref.		
Normal	453 (99.6%)	385 (99.7%)	68 (98.6%)	0.18 (0.00-6.99)		
G:					0.32	455
High	95 (20.9%)	77 (19.9%)	18 (26.1%)	Ref.		
Normal	360 (79.1%)	309 (80.1%)	51 (73.9%)	0.70 (0.39-1.30)		
Surgical approach					<0.001	455
Distal-Billroth 1	155 (34.1%)	146 (37.8%)	9 (13.0%)	Ref.		
Distal-Billroth 2	6 (1.32%)	4 (1.04%)	2 (2.90%)	8.11 (0.91-50.9)		
Distal-Roux-en-Y	68 (14.9%)	50 (13.0%)	18 (26.1%)	5.74 (2.46-14.3)		
Proximal	8 (1.76%)	7 (1.81%)	1 (1.45%)	2.54 (0.09-17.4)		
Total-Roux-en-Y	218 (47.9%)	179 (46.4%)	39 (56.5%)	3.48 (1.70-7.93)		
Blood transfusion:					0.123	455
No	433 (95.2%)	370 (95.9%)	63 (91.3%)	Ref.		
Yes	22 (4.84%)	16 (4.15%)	6 (8.70%)	2.23 (0.76-5.71)		

Implantation of nutrition tubes:					0.025	455
No	237 (52.1%)	192 (49.7%)	45 (65.2%)	Ref.		
Yes	218 (47.9%)	194 (50.3%)	24 (34.8%)	0.53 (0.31-0.90)		
Intraoperative gastroscopy:					1	455
No	437 (96.0%)	370 (95.9%)	67 (97.1%)	Ref.		
Yes	18 (3.96%)	16 (4.15%)	2 (2.90%)	0.74 (0.11-2.69)		
Operating time > 4 h:					<0.001	455
No	254 (55.8%)	231 (59.8%)	23 (33.3%)	Ref.		
Yes	201 (44.2%)	155 (40.2%)	46 (66.7%)	2.96 (1.74-5.17)		
Blood loss > 100 mL:					<0.001	455
No	321 (70.5%)	289 (74.9%)	32 (46.4%)	Ref.		
Yes	134 (29.5%)	97 (25.1%)	37 (53.6%)	3.43 (2.03-5.85)		
